Effects of circadian rhythm disruption on retinal physiopathology: Considerations from a consensus of experts.
Circadian rhythm
age related macular degeneration
chronoprotection
melatonin
Journal
European journal of ophthalmology
ISSN: 1724-6016
Titre abrégé: Eur J Ophthalmol
Pays: United States
ID NLM: 9110772
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
pubmed:
4
6
2022
medline:
13
8
2022
entrez:
3
6
2022
Statut:
ppublish
Résumé
The circadian rhythms originate within the organism and synchronize with cyclic fluctuations in the external environment. It has been demonstrated that part of the human genome is under control of the circadian clock and that a synchronizer that helps to maintain daily rhythms is Melatonin, a neuro-hormone primarily synthesized by the pineal gland during the night. The chronic disruption of circadian rhythm has been linked to many conditions such as obesity, metabolic syndrome, type 2 diabetes, cancer, and neurodegenerative diseases. Studies in the mice showed that the disruption of the retinal circadian rhythm increases the decline during the aging of photoreceptors, accelerating age-related disruption of cone cell structure, function, and viability and that the melatonin receptor deletion seems to influence the health of retinal cells, speeding up their aging. In conclusion, preserving the circadian rhythms could be to add to the prevention and treatment of age-related degenerative retinal diseases, and although additional studies are needed, melatonin could be a valid support to favor this "chronoprotection action".
Identifiants
pubmed: 35656746
doi: 10.1177/11206721221106149
pmc: PMC9373193
doi:
Substances chimiques
Melatonin
JL5DK93RCL
Types de publication
Editorial
Langues
eng
Sous-ensembles de citation
IM
Pagination
2489-2493Références
Bioessays. 2014 Aug;36(8):778-87
pubmed: 24903552
Prog Retin Eye Res. 2014 Mar;39:58-76
pubmed: 24333669
Mol Vis. 2010 Dec 07;16:2605-11
pubmed: 21151601
Eur Rev Med Pharmacol Sci. 2016 Oct;20(20):4196-4201
pubmed: 27831657
Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3342-7
pubmed: 17360649
J Natl Cancer Inst. 2001 Oct 17;93(20):1563-8
pubmed: 11604480
Invest Ophthalmol Vis Sci. 2016 Jan 1;57(1):94-104
pubmed: 26780313
Mol Cell Endocrinol. 2006 Jun 27;252(1-2):57-68
pubmed: 16644097
Nat Rev Genet. 2017 Mar;18(3):164-179
pubmed: 27990019
Cell Tissue Res. 2007 Oct;330(1):29-34
pubmed: 17701055
Nutr Rev. 2003 Oct;61(10):342-6
pubmed: 14604266
Science. 1976 Dec 3;194(4269):1071-4
pubmed: 982063
Exp Eye Res. 2017 Dec;165:90-95
pubmed: 28941766
Prog Retin Eye Res. 2008 Mar;27(2):137-60
pubmed: 18316227
Nat Genet. 2012 Jan 29;44(3):297-301
pubmed: 22286214
Vis Neurosci. 1999 Sep-Oct;16(5):909-18
pubmed: 10580726
Science. 2010 Dec 3;330(6009):1349-54
pubmed: 21127246
Cell. 2000 Dec 22;103(7):1009-17
pubmed: 11163178
PLoS One. 2012;7(5):e37799
pubmed: 22629458
Invest Ophthalmol Vis Sci. 2018 Oct 1;59(12):4856-4870
pubmed: 30347082
Invest Ophthalmol Vis Sci. 2009 Jul;50(7):3495-502
pubmed: 19234351
Chronobiol Int. 2016;33(8):1101-19
pubmed: 27308960
Neurosci Lett. 2011 Apr 20;494(1):61-4
pubmed: 21362461
Brain Res. 1993 Mar 12;605(2):256-64
pubmed: 8481775
J Gen Physiol. 1985 Nov;86(5):671-89
pubmed: 2999294
J Clin Endocrinol Metab. 2016 Mar;101(3):1066-74
pubmed: 26771705
Proc R Soc Lond B Biol Sci. 1987 Apr 22;230(1260):339-54
pubmed: 2438704
Science. 2002 Dec 13;298(5601):2213-6
pubmed: 12481141
Exp Eye Res. 2012 Oct;103:82-9
pubmed: 22960156
Invest Ophthalmol Vis Sci. 1980 Nov;19(11):1268-73
pubmed: 7429763
J Pineal Res. 2007 Jan;42(1):83-91
pubmed: 17198542
J Pathol. 2007 Aug;212(4):429-39
pubmed: 17582234
Cell. 2007 Aug 24;130(4):730-741
pubmed: 17719549
Yale J Biol Med. 2019 Jun 27;92(2):233-240
pubmed: 31249484
J Cell Sci Suppl. 1993;17:189-95
pubmed: 8144697
J Exp Med. 2004 Dec 20;200(12):1539-45
pubmed: 15596525
Mol Vis. 2009 Aug 21;15:1673-9
pubmed: 19710945
Bioessays. 2008 Jul;30(7):624-33
pubmed: 18536031
Proc Natl Acad Sci U S A. 2018 Dec 18;115(51):13099-13104
pubmed: 30498030